Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Homology Medicines, Inc. | fixx-ex322_7.htm |
EX-31.2 - EX-31.2 - Homology Medicines, Inc. | fixx-ex312_10.htm |
EX-31.1 - EX-31.1 - Homology Medicines, Inc. | fixx-ex311_12.htm |
EX-23.1 - EX-23.1 - Homology Medicines, Inc. | fixx-ex231_6.htm |
EX-10.2 - EX-10.2 - Homology Medicines, Inc. | fixx-ex102_943.htm |
EX-4.4 - EX-4.4 - Homology Medicines, Inc. | fixx-ex44_13.htm |
10-K - 10-K - Homology Medicines, Inc. | fixx-10k_20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Arthur O. Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines, Inc. (the “Company”) hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
|
(1) |
The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Report”) fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 11, 2021 |
|
By: |
/s/ Arthur O. Tzianabos, Ph.D. |
|
|
|
Arthur O. Tzianabos, Ph.D. |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |